Respiratory syncytial virus immune globulin Alternatives Compared
| Respiratory syncytial virus immune globulin | Ribavirin | Synagis (palivizumab) |
|
|---|
| Respiratory syncytial virus immune globulin | Ribavirin | Synagis (palivizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for RSV. Respiratory syncytial virus immune globulin may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hepatitis C, RSV. Ribavirin may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for RSV Vaccination and Immunization, RSV. Synagis may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||
| More about Respiratory syncytial virus immune globulin | More about Ribavirin | More about Synagis (palivizumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Ribavirin has an average rating of 5.1 out of 10 from a total of 10 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 44% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
Lower cost generic |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ribavirin prices |
View all Synagis prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
|
N/A |
Rebetol, RibaTab, Virazole |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
N/A |
960 hours |
432 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 97 drugs are known to interact with Respiratory syncytial virus immune globulin:
|
A total of 18 drugs are known to interact with Ribavirin:
|
A total of 3 drugs are known to interact with Synagis:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
June 03, 1998 |
June 19, 1998 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.